1 Risk Intervention Study: Cisapride Evelyn M Rodriguez MD, MPH Director, DDREII, OPDRA.

Slides:

Advertisements

Similar presentations

ACCF/AHA Clopidogrel Clinical Alert: Approaches to the FDA “Boxed Warning” A Report of the American College of Cardiology Foundation Task Force on Clinical.

Advertisements

Quality Improvement/ Quality Assurance Amelia Broussard, PhD, RN, MPH Christopher Gibbs, JD, MPH.

Using AHRQ Prevention Quality Indicators to Assess Program Performance in Medicaid Managed Care Sandra K. Mahkorn MD, MPH, MS Chief Medical Officer Wisconsin.

Program Evaluation and Measurement Janet Myers. Objectives for today… To define and explain concepts and terms used in program evaluation. To understand.

ECONOMIC ASSESSMENT OF IMPLEMENTATION TREATMENT GUIDELINES OF HYPERTENSION IN OUT-PATIENT PRACTICE Kulmagambetov IR Karaganda State Medical Academy, Kazakhstan.

Objectives Why we need DHCPL Situations that call for a DHCPL Definitions DHCPL itself–content, presentation, process Target audience Current and future.

Guidance for Industry Establishing Pregnancy Registries Pregnancy Registry Working Group Pregnancy Labeling Taskforce March, 2000 Evelyn M. Rodriguez M.D.,

Prescription Opioid Use and Opioid-Related Overdose Death — TN, 2009–2010 Jane A.G. Baumblatt, MD Centers for Disease Control and Prevention Epidemic Intelligence.

Improving Decision-Making for Medications in Rheumatoid Arthritis Edward Yelin, Ph.D. Jennifer Barton, M.D. Laura Trupin, M.P.H. Gina Evans-Young University.

1 Alvimopan RiskMAP Joyce Weaver, Pharm.D., BCPS Office of Surveillance and Epidemiology.

Community Planning Training 1-1. Community Plan Implementation Training 1- Community Planning Training 1-3.

History of the Other Work of the SACHDNC Alex R. Kemper, MD, MPH, MS September 22, 2011.

Continuing Medical Education Program. The University of South Carolina School of Medicine-Palmetto Health Continuing Medical Education Organization The.

IPhVWP Polish Presidency, Warsaw October 6 th 2011 Almath Spooner Irish Medicines Board Monitoring the outcome of risk minimisation activities.

Darren A. DeWalt, MD, MPH Division of General Internal Medicine Maihan B. Vu, Dr.PH, MPH Center for Health Promotion and Disease Prevention University.

Yesterday, today, and tomorrow

1 Safety Pharmacology for Oncology Pharmaceuticals at CDER John K. Leighton Associate Director for Pharmacology CDER/OND/OODP.

IMPROVING DIABETES MANAGEMENT IN PRIMARY CARE

1 Just The Facts Ma’am Dementia Care & Anti-Psychotics Just The Facts Ma’am December 17, 2012 Ronald A. Savrin, MD, MBA, FACS Medical Director, Ohio KePRO.

Adverse Drug Event Reporting

Overview of Issues for Psychopharmacological Drugs Advisory Committee June 16, 2003 WBC Monitoring for Clozapine Judith A. Racoosin, MD, MPH Safety Team.

Postmarketing Safety Assessment of Osteonecrosis of the Jaw Pamidronate & Zoledronic Acid Division of Drug Risk Evaluation Office of Drug Safety FDA Carol.

IPhVWP Polish Presidency, Warsaw October 6 th 2011 Almath Spooner Irish Medicines Board Monitoring the outcome of risk minimisation activities.

Reproductive Health Drugs, Pregnancy Labeling Subcommittee Meeting March 28-29, 2000 Holli A. Hamilton, M.D., M.P.H. Pregnancy Labeling Team Office of.

1 EPI235: Epi Methods in HSR April 17, 2007 L5 Program Evaluation with Longitudinal Data 1: Applications (Dr. Schneeweiss) Various examples of applications.

Chapter 6 CRISIS MANAGEMENT. Introduction - Crisis: ◦is a situation that specifically involves a pharmaceutical product, medical device or activity with.

1 LYMErix  Lyme Disease Vaccine (Recombinant Osp A) Center for Biologics Evaluation and Research May 21, 2002.

Regulatory History of Sibutramine Eric Colman, MD Division of Metabolism and Endocrinology Products CDER - FDA.

Risk of Serious Cardiac Events in Older Adults Using Antipsychotic Agents Sandhya Mehta, MS; Hua Chen, MD, PhD; Michael Johnson, PhD; and Rajender R. Aparasu,

1 PhRMA Guiding Principles - DTC About Prescription Medicines.

Population-Based Epidemiologic Safety Studies: Overview and Challenges Drug Safety and Risk Management Advisory Committee Silver Spring, Maryland June.

1 Postmarketing Drug Safety and Risk Intervention Studies Evelyn M Rodriguez MD, MPH Director, DDREII, OPDRA.

Sidney M. Wolfe M.D and Sherri Shubin M.D., M.P.H. Public Citizen’s Health Research Group FDA Drug Safety and Risk Management and Dermatologic and Ophthalmic.

Summary of Findings Improving the System of Reporting and Interpreting Unexpected Serious Adverse Events to Investigators Conducting Research Under an.

Reducing Pain Medication Deaths in Utah: Physician Education and Practice Redesign Final Report by: HealthInsight June 2009.

Beyond ePrescribing Factors Influencing Patient Safety in Medical Group Practices - September 26 th, 2007 AHRQ 2007: Improving Healthcare, Improving Live.

Basic Nursing: Foundations of Skills & Concepts Chapter 9

Maine Prenatal Collaborative Susan Swartz, M.D. Judy Soper, RT(R), RDMS, BS Tim Cowan, MSPH Principal Investigator Project Director Data Analyst December.

1 QTc and Quinolones: recent regulatory actions Joyce Korvick M.D., M.P.H. Office of Drug Evaluation IV Division of Special Pathogens FDA.

Poor Research Designs in Policy Impact Studies: “Lies, Damn Lies, and Statistics” AHRQ 2007 Annual Conference: Improving Healthcare, Improving Lives September.

1 ADHD drugs and CV outcomes: Preliminary feasibility results and potential observational studies David J. Graham, MD, MPH on behalf of the FDA Epidemiology.

A Claims Database Approach to Evaluating Cardiovascular Safety of ADHD Medications A. J. Allen, M.D., Ph.D. Child Psychiatrist, Pharmacologist Global Medical.

General Regulatory Issues in the Development of Drugs Intended for Treatment of Chronic Illness Sharon Hertz, M.D. Medical Officer Division of Anesthetic,

July 15, Postmarketing Safety Evaluation of Approved Drugs and Risk Management Victor F. C. Raczkowski, MD, MS Director, Office of Drug Safety July.

October 28, F OOD AND DRUG ADMINISTRATION AMENDMENTS ACT OF 2007 (FDAAA) and Risk Evaluation and Mitigation Strategies (REMS) Presented to the Ninth.

27 June 2000Victor F. C. Raczkowski, M.D.1 Benefit-Risk Reevaluation of Marketed Drugs Victor F. C. Raczkowski, M.D., M.S. Gastrointestinal Drugs Advisory.

Risk Management of Modified- Release Opiate Analgesics: Palladone Sharon Hertz, M.D. Medical Team Leader, Analgesics Division of Anesthetic, Critical Care,

Questions to Committee about Potential Cancer Risk with Use of Topical Immunosuppressants (Calcineurin Inhibitors) Question 1: Messages about Risk A. Based.

Review Update: QT Prolongation with Citalopram and Escitalopram Pediatric Advisory Committee Meeting November 16, 2006 Prepared by M. Lisa Jones, MD Division.

Comments on FDA Concept Paper Sidney N. Kahn, MD, PhD President Pharmacovigilance & Risk Management, Inc. Risk Assessment of Observational.

Developing, Pilot Testing & Evaluating RiskMAP Interventions Annette Stemhagen, DrPH, FISPE Vice President UBC Epidemiology & Risk Management The FDA Regulatory.

27 June 2000Victor F. C. Raczkowski, M.D.1 Risk-Management Options Victor F. C. Raczkowski, M.D., M.S. Gastrointestinal Drugs Advisory Committee 27 June.

Do Decision Aids Promote Shared Decision-Making for Prostate Cancer Screening? Alex Krist MD Steven Woolf MD MPH Robert Johnson PhD Department of Family.

Viagra (sildenafil citrate): Extensive Clinical and Post-Marketing Experience Michael Sweeney, MD Senior Medical Director Pfizer Inc.

Antipsychotic Medications: Prevalence of Inappropriate Use, Polypharmacy, and Non-Adherence Nancy G. Pham, PharmD; Lisa Le, MS; Karen M. Stockl, PharmD;

ADHD drugs and CV outcomes: Preliminary feasibility study results David J. Graham, MD, MPH on behalf of the FDA Epidemiology Contracts Study Team DSARM.

PRAGMATIC Study Designs: Elderly Cancer Trials

Division of Cardiovascular Devices

Patient Focused Drug Development An FDA Perspective

FDA’s IDE Decisions and Communications

MacColl Center for Health Care Innovation

National Pharmacy Practice Standards the Regulatory Role

Black Box Warning What You Need To Know.

Secretary’s Task Force on Black & Minority Health, 1985

Evaluation of Immunization Standing Orders Programs in North Carolina Hospitals Presented by Wayne L. Anderson Ph.D.1, Amanda Honeycutt Ph.D.1, Kathleen.

Statement on Concerta and Methylphenidate for the June 30, 2005 Pediatric Advisory Committee The FDA has identified two possible safety concerns with.

AndroGel Package Label Changes

Regulatory Perspective of the Use of EHRs in RCTs

Copyright Notice This presentation is copyrighted by the Psychopharmacology Institute. Subscribers can download it and use it for professional use. The.

Presentation transcript:

1 Risk Intervention Study: Cisapride Evelyn M Rodriguez MD, MPH Director, DDREII, OPDRA

2 Topics for Today’s Discussion Cisapride: Risk Intervention Case Study Summary / Considerations Future Directions

3 Cisapride’s Regulatory History Risk Intervention Study

4 Cisapride’s Regulatory History Approved in July 1993 First reports of Ventricular Arrhythmia with an antifungal drug 12/94 Multiple Dear Healthcare Practitioner letters that described new contraindications and warnings for specific drugs and conditions

5 Cisapride’s Regulatory History Black Box Warning with Contraindication for QT interval prolonging drugs and Cardiovascular and Medical Conditions, 2nd line indication & DHPL 6/98

6 Study Objective To describe the impact of the cumulative labeling changes through 6/98 –CYP P450 3A4 Enzyme Inhibitor Drugs –QT Prolonging Drugs –Contraindicated Comorbidities

7 Methods Automated Databases: –Sites A, B, and C Time Periods –Before DHPL: 7/97 - 6/98 –After DHPL: 7/98 - 6/99

8 Study Sites N based on calendar 1998; no material change for any of databases in 1999.

9 Cohorts Before and After Labeling Changes through 6/98

10 Results: Contraindicated Drug or Disease

11 Conclusion No reduction in contraindicated use was found following labeling changes and DHPL of 6/98

12 Study Group FDA Investigators Diane Wysowski Ph.D., Evelyn M. Rodriguez, Dave Graham M.D., M.P.H. United Health Group (Site A) Deborah Shatin, Ph.D., Stephanie D. Schech, Ph.D. Tennessee Medicaid (Site B) Walter Smalley, M.D., M.P.H., Jim Daugherty, M.S., Wayne Ray, Ph.D. Harvard Consortium (Site C) Jerry Gurwitz, M.D, Susan Andrade, D.Sc., Jackie Cernieux, M.P.H. (Meyers Primary Care Institute, Fallon Healthcare System); Richard Platt, M.D., M.S., Arnold Chan, M.D., Dr.P.H. (Harvard Pilgrim Healthcare, Michael Goodman, Ph.D. (HealthPartners)

13 Summary / Considerations Risk Intervention studies are useful to assess the effect of labeling and DHPL This study suggests labeling fatigue Other strategies, such as Education targeting Prescribers and Patients, may be useful to encourage the implementation of recommended risk management efforts

14 Future Directions Determine –How prescribers interpret information from DHPL & other educational materials –Best format to inform prescribers and patients of drug safety concerns -- PPI, Med Guide, company sales force materials, CME course

15 Future Directions Determine –How information, contraindications, and monitoring recommendations are used

16 Future Directions Conduct risk intervention studies in multiple databases that reflect the range of health care services delivery systems Validate the findings in databases with medical record review

17 Possible Next Steps Incidence Study for Serious Outcomes –QT Prolongation and Torsades de Pointe difficult to assess (non-specific ICD-9 codes and underreporting) –Sudden Death possible; use unexposed comparator group

18 Possible Next Steps Implement Risk Interventions: EKG monitoring, other Evaluate whether the Risk Interventions (e.g. Education, Labeling) is achieving desired goals

19 Back Up Slides

20 Contra- indicated Drugs

21 Contraindicated Comorbidity Based on (pre/post) persons with 180+ days of enrollment: Site A: 13613/12418; B: 4379/4229; C: 6848/5812